A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

July 21, 2025

Study Completion Date

July 21, 2025

Conditions

Pain

Interventions

DRUG

VX-973

Suspension for oral administration.

DRUG

Placebo

Suspension for oral administration.

Trial Locations (1)

ICON Salt Lake City, Salt Lake City

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT06615570 - A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants | Biotech Hunter | Biotech Hunter